News from kyowa kirin international A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

06 Jan, 2020, 09:00 GMT Kyowa Kirin Announces Marketing Authorisation Application for Istradefylline Validated by European Medicines Agency

Kyowa Kirin Co., Ltd. (TSE: 4151) President and CEO: Masashi Miyamoto, "Kyowa Kirin") today announces that its marketing authorisation application...


21 Sep, 2018, 12:00 BST Kyowa Kirin Announces Mogamulizumab Received Positive CHMP Opinion for the Treatment of Mycosis Fungoides and Sézary Syndrome

If approved, mogamulizumab would be the first biologic agent targeting CCR4 to be available for patients in Europe. Kyowa Hakko Kirin Co., Ltd.,...


05 Sep, 2018, 10:40 BST NICE Backs Crysvita® (Burosumab) for Rare Metabolic Bone Disorder, X-linked Hypophosphataemia (XLH)

The positive recommendation marks a step change in the management of XLH for children and young people, and the first significant clinical...


10 Oct, 2017, 13:30 BST Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab's Biologics License Application

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...


24 Aug, 2017, 13:30 BST Ultragenyx and Kyowa Hakko Kirin Announce Submission of Burosumab's Biologics License Application in the US

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...


24 Aug, 2017, 13:30 BST Kyowa Hakko Kirin and Kyowa Kirin International Announce Burosumab Data Presentations at ASBMR 2017 Annual Meeting

Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) and Kyowa Kirin International PLC (Kyowa Kirin International), a wholly owned subsidiary of Kyowa...


06 Apr, 2017, 13:30 BST Ultragenyx and Kyowa Kirin International Announce Positive Data from Paediatric Phase 2 Studies of Burosumab (KRN23) in X-Linked Hypophosphatemia

Sustained reduction in bone disease and improvement in growth through 64 weeks of treatment and sustained effect on bone mineral metabolites in...


05 Jan, 2017, 07:00 GMT Ultragenyx and Kyowa Kirin International Announce Marketing Authorisation Application for KRN23 Filed and Accepted for Review by European Medicines Agency

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Kyowa Kirin International PLC (KKI), a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd....